These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mast cells involvement in the inflammation and fibrosis development of the TNBS-induced rat model of colitis. Xu X; Weksler-Zangen S; Pikarsky A; Pappo O; Wengrower D; Bischoff SC; Pines M; Rivkind A; Goldin E; Levi-Schaffer F Scand J Gastroenterol; 2002 Mar; 37(3):330-7. PubMed ID: 11916196 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556 [TBL] [Abstract][Full Text] [Related]
5. Features of intestinal lesions in the clinical course of inflammatory bowel diseases. Vetuschi A; Latella G; Pompili S; Gaudio E; Sferra R Ital J Anat Embryol; 2014; 119(3):286-303. PubMed ID: 26749690 [TBL] [Abstract][Full Text] [Related]
6. Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts. Koo JB; Nam MO; Jung Y; Yoo J; Kim DH; Kim G; Shin SJ; Lee KM; Hahm KB; Kim JW; Hong SP; Lee KJ; Yoo JH BMC Gastroenterol; 2017 Jun; 17(1):73. PubMed ID: 28592228 [TBL] [Abstract][Full Text] [Related]
12. Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Fox CC; Lichtenstein LM; Roche JK Dig Dis Sci; 1993 Jun; 38(6):1105-12. PubMed ID: 7685262 [TBL] [Abstract][Full Text] [Related]
13. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Powell DW; Mifflin RC; Valentich JD; Crowe SE; Saada JI; West AB Am J Physiol; 1999 Aug; 277(2):C183-201. PubMed ID: 10444394 [TBL] [Abstract][Full Text] [Related]
14. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Rieder F; Fiocchi C Curr Opin Gastroenterol; 2008 Jul; 24(4):462-8. PubMed ID: 18622160 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Holvoet T; Devriese S; Castermans K; Boland S; Leysen D; Vandewynckel YP; Devisscher L; Van den Bossche L; Van Welden S; Dullaers M; Vandenbroucke RE; De Rycke R; Geboes K; Bourin A; Defert O; Hindryckx P; De Vos M; Laukens D Gastroenterology; 2017 Oct; 153(4):1054-1067. PubMed ID: 28642198 [TBL] [Abstract][Full Text] [Related]
16. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Lawrance IC; Maxwell L; Doe W Inflamm Bowel Dis; 2001 Aug; 7(3):226-36. PubMed ID: 11515849 [TBL] [Abstract][Full Text] [Related]
17. Mast cells and eosinophils have a potential profibrogenic role in Crohn disease. Xu X; Rivkind A; Pikarsky A; Pappo O; Bischoff SC; Levi-Schaffer F Scand J Gastroenterol; 2004 May; 39(5):440-7. PubMed ID: 15180181 [TBL] [Abstract][Full Text] [Related]
18. From inflammation to lesion. Geboes K Acta Gastroenterol Belg; 1994; 57(5-6):273-84. PubMed ID: 7709695 [TBL] [Abstract][Full Text] [Related]
19. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Sartor RB Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232 [TBL] [Abstract][Full Text] [Related]
20. Mucosal remodeling in long-standing ulcerative colitis with colorectal neoplasia: significant alterations of NCAM+ or alpha-SMA+ subepithelial myofibroblasts and interstitial cells. Okayasu I; Yoshida T; Mikami T; Hana K; Yokozawa M; Araki K; Mitsuhashi J; Kikuchi M; Adachi E; Sada M Pathol Int; 2009 Oct; 59(10):701-11. PubMed ID: 19788615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]